MedTrace Logo

Eze/Simva Switch Study in Diabetics (0653A-807)

NCT00541697 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 648

Last updated 2024-08-15

No results posted yet for this study

Summary

A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks

DRUG

Comparator: atorvastatin / Duration of Treatment: 6 Weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-19
Primary Completion
2005-09-28
Completion
2005-10-14

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00541697 on ClinicalTrials.gov